Featured Research

from universities, journals, and other organizations

TB treatment paradox: Mouse studies show body's own response helps TB bacteria survive

Date:
June 28, 2012
Source:
Johns Hopkins Medical Institutions
Summary:
Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could -- paradoxically -- shorten treatment time for the highly contagious lung infection according to new research.

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could -- paradoxically -- shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research.

Shorter duration of drug therapy is key, researchers say, to increase treatment compliance for the growing global health threat posed by the disease.

In experiments described in the June 27 issue of PLoS ONE, the Johns Hopkins investigators compared a group of TB-infected mice receiving standard TB treatment of rifampin, isoniazid and pyrazinamide with another group that received standard TB treatment plus etanercept, a drug used to inhibit a protein known as tumor necrosis factor alpha, or TNF-α, to prevent immune responses.

TB infection causes an immune response that notoriously includes production of TNF-α, which is critical for the formation of TB granulomas -- the hallmark tumors that form in the lungs and other parts of the body when the immune system tries to contain these bacteria. Paradoxically, this immune response is believed to wall off the bacteria, creating a sanctuary for "persistent" bacteria and, in turn, leading to the need for extended courses of treatment. Compliance with such treatment -- daily doses of antibiotics for six months or more -- is particularly challenging in the developing world and has fueled an epidemic of multi-drug resistant TB, the researchers say.

"New and shorter TB treatments are needed to stop this scourge globally, but current treatments largely target actively replicating bacteria, rather than slow-replicating, persistent TB bacteria," says Sanjay Jain, M.D., an infectious disease specialist at Hopkins Children's Center and the senior author of this study.

Aware that TB patients taking TNF-α inhibitors to treat other conditions such as rheumatoid arthritis and Crohn's disease can "wake up" persistent TB bacteria, Jain and his team speculated that it might be possible to shorten TB treatments by using TNF-α inhibitors that keep microbes "awake" so that they could be "zapped" with standard TB treatments.

"We were surprised to find that this paradoxical approach actually works in mouse models of TB," Jain says.

During the initial six weeks of treatment, when TB bacteria were actively replicating, there was no significant difference in bacterial killing observed between the two groups of mice, Jain noted. But at weeks eight and 10, the group receiving standard TB treatment plus etanercept had a significantly lower bacterial burden than the group receiving just the standard TB treatment.

"This finding is important because it is during this later phase of infection and treatment, that TB bacteria multiply much more slowly, making up the so-called 'persisters' that lie 'asleep' and require protracted treatment," says Ciaran Skerry, Ph.D., the journal report's first author.

At 12 weeks, both groups had no bacteria visible on culture, but 27.8 percent of the group receiving standard TB treatment relapsed, while only 10.5 percent of the ones treated with the standard treatment plus etanercept relapsed.

Jain says due to risks of reactivation disease with the use of TNF-α inhibitors, more studies for safety and efficacy need to be done in the laboratory before the treatment can be used in people.

The research was funded by the NIH Director's New Innovator Award under grant OD006492 to Sanjay K. Jain.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ciaran Skerry, Jamie Harper, Mariah Klunk, William R. Bishai, Sanjay K. Jain. Adjunctive TNF Inhibition with Standard Treatment Enhances Bacterial Clearance in a Murine Model of Necrotic TB Granulomas. PLoS ONE, 2012; 7 (6): e39680 DOI: 10.1371/journal.pone.0039680

Cite This Page:

Johns Hopkins Medical Institutions. "TB treatment paradox: Mouse studies show body's own response helps TB bacteria survive." ScienceDaily. ScienceDaily, 28 June 2012. <www.sciencedaily.com/releases/2012/06/120628145750.htm>.
Johns Hopkins Medical Institutions. (2012, June 28). TB treatment paradox: Mouse studies show body's own response helps TB bacteria survive. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2012/06/120628145750.htm
Johns Hopkins Medical Institutions. "TB treatment paradox: Mouse studies show body's own response helps TB bacteria survive." ScienceDaily. www.sciencedaily.com/releases/2012/06/120628145750.htm (accessed September 23, 2014).

Share This



More Plants & Animals News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Raw: Tiger Kills Man at India Zoo

Raw: Tiger Kills Man at India Zoo

AP (Sep. 23, 2014) A white tiger killed a young man who climbed over a fence at the New Delhi zoo and jumped into the animal's enclosure on Tuesday, a spokesman said. (Sept. 23) Video provided by AP
Powered by NewsLook.com
Cat Lovers Flock to Los Angeles

Cat Lovers Flock to Los Angeles

AFP (Sep. 22, 2014) The best funny internet cat videos are honoured at LA's Feline Film Festival. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com
Washed-Up 'Alien Hairballs' Are Actually Algae

Washed-Up 'Alien Hairballs' Are Actually Algae

Newsy (Sep. 22, 2014) Green balls of algae washed up on Sydney, Australia's Dee Why Beach. Video provided by Newsy
Powered by NewsLook.com
Raw: San Diego Zoo Welcomes Cheetah Cubs

Raw: San Diego Zoo Welcomes Cheetah Cubs

AP (Sep. 20, 2014) The San Diego Zoo has welcomed two Cheetah cubs to its Safari Park. The nearly three-week-old female cubs are being hand fed and are receiving around the clock care. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Plants & Animals

Earth & Climate

Fossils & Ruins

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins